Meta-analysis of immune-related adverse events in phase 3 clinical trials assessing immune checkpoint inhibitors for lung cancer
Alvise Berti, Roberto Bortolotti, Mariachiara Dipasquale, Stefania Kinspergher, Larry J. Prokop, Guido Grandi, S. Inchiostro, Giuseppe Paolazzi, Orazio Caffo, Antonello Veccia
Topics & Concepts
MedicineAtezolizumabNivolumabDurvalumabDiscontinuationAdverse effectPembrolizumabInternal medicineLung cancerOncologyClinical trialImmunotherapyRandomized controlled trialCancerCancer Immunotherapy and BiomarkersLung Cancer Research StudiesLung Cancer Treatments and Mutations